The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The thing is you can't take them seriously. They said the same about many multiples of the SP for a buyout when it was 150p.
Who is going to pay £200m for a revenue of £6m?
It is cleared as a novel device to capture intacts CTCs in MBC to a standard that the FDA are satisfied with.
It is currently labelled for Research Use only because by itself it can only be used for research.
How it is used in future depends on who runs trials to assess it's use as a clinical diagnostic.
Research use only covers pharma drug trials so it does have a commercial use with both products and services.
None of my posts have been deleted.
I said Parsortix was cleared by the FDA as a novel device to capture CTCs for further analysis.
I don't dispute that Angle can offer service solutions in house to pharma companies for trials.
The point is it is only approved for MBC if clinicians want to build a diagnostic test using it.
Two separate things
Some companies are already using the Cellsearch system for this and also CTdna.
Neither of these are ideal but it is hard to get people to change their ways sometimes.
Hence Angle's efforts to "educate" the market.
OK I acknowledge that it's on the slide.
But they still aren't all HER2 trials, which is what the Portrait assay is being used for
Also if the Eisai trial has 208 participants and they are charging £5k why is the current contract only £250k
Eisai do not have 60k oncology patients in trials.
The trial is for the use of the specific Portrait HER2 assay so would only apply to other drugs Eisai have targeting HER2.
Stop lying
Taken another look at the Eisai trial. Notably it involves not only Parsortix but the Portrait HER2 assay.
I think the reference to multiple clinical trials that could use the Portrait HER2 assay, they mean other companies taking an interest.
So while they may get repeat business from Eisai, it's more the case that they hope to target business from other companies with similar HER2 targeting drugs.
The high sales of the drug Enhertu for breast cancer has led other companies like Eisai and BionTech to try and find similar candidates.
BionTech so far only seem to have used CTdna to screen patients for their trials.
There are some other companies so the hope is that this will lead to the multiple clinical trials.
I mean it just shows the riff raff Angle attracts.
I can only compare to the recent GROW presentation I attended which required a bow tie.
Were you the one wearing the hoodie?
Unfortunately women are not really my bag.
This is your bag though. Hold it tight!
Some of us investors don't stop at 4.30.
Not when US markets are open for another 4.5 hours.
Lot of better apps there than on the moribund UK market!
Funny, Tom was saying just the same thing the other day!
Clearly you are working together though.
Wow your first post in over 2 years. And one of your last ones referenced wait for it......dedederrrr
TomHUK.
Almost as if you are one of Tom's other accounts. It's funny you sound a bit like him too...
I agree Bojo that investors need to take responsibility for their own decisions and do more to scrutinize the market.
Newland is quite a charismatic showman and it is easy to feel confident in him.
There was talk prior to the FDA clearance about rapid opportunities to grow the business.
It's very hard for individual investors to do the kind of market analysis that you describe.
And yet Angle are reliant on small retail shareholders because they are incapable of attracting fund managers.
It sounds like all your research is based on quick Google searches.
It's worth taking the time in life to take calm, thoughtful measured decisions, rather than jumping around like a headless chicken!
Well they must be pretty clueless if they turn up to an evening event dressed like that.
None of them look like professional investors who would wear a suit.
Note how many times the word diagnostic appears in that piece.
The only pharma co mentioned is Roche, which has a diagnostics arm.
When I say you don't know what you are talking about, I am referring to the fact that you don't seem to understand the difference between a pharmaceutical company and a medtech or diagnostics company.
Love the way not one of the attendees was wearing a suit.
One of them even had a hoodie on ffs